• LAST PRICE
    25.6400
  • TODAY'S CHANGE (%)
    Trending Up0.4200 (1.6653%)
  • Bid / Lots
    21.0000/ 2
  • Ask / Lots
    38.4000/ 20
  • Open / Previous Close
    25.1400 / 25.2200
  • Day Range
    Low 24.3592
    High 25.7000
  • 52 Week Range
    Low 9.0000
    High 37.7114
  • Volume
    36,813
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 25.22
TimeVolumeOPNT
09:32 ET15325.14
09:35 ET69325.0001
09:39 ET10025.05
09:44 ET61924.3592
09:46 ET129125
09:55 ET849525
10:00 ET20025.35
10:13 ET20025.385
10:18 ET44025.375
10:22 ET10025.38
10:26 ET20025.01
10:27 ET10025.09
10:29 ET33025.32
10:44 ET20025.32
11:00 ET50025.5
11:05 ET50025.37
11:20 ET10025.6899
11:48 ET10025.03
11:50 ET80025.43
11:57 ET40025.337
12:03 ET20025.35
12:24 ET10025.22
12:26 ET70025.1001
12:42 ET20025.12
01:00 ET22025.425
01:02 ET17425.392
01:04 ET10025.5
01:27 ET10025.34
01:29 ET10025.34
01:44 ET10025.1301
02:48 ET170025.53
02:50 ET10025.68
02:54 ET22525.415
02:59 ET10025.49
03:03 ET178125.68
03:21 ET10025.61
03:39 ET10025.42
03:42 ET40025.47
03:51 ET10025.505
03:53 ET10025.4
03:55 ET20025.43
03:57 ET150025.6283
04:00 ET203425.64
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOPNT
Opiant Pharmaceuticals Inc
121.0M
528.7x
---
United StatesLJPC
La Jolla Pharmaceutical Co
125.2M
14.1x
---
United StatesDRRX
DURECT Corp
150.1M
-3.8x
---
United StatesWVE
WAVE Life Sciences Ltd
128.3M
-0.9x
---
United StatesNXTC
NextCure Inc
148.1M
-2.2x
---
United StatesCSBR
Champions Oncology Inc
107.8M
301.5x
---
As of 2022-01-22

Company Information

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company’s pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Contact Information

Headquarters
233 Wilshire Blvd, Suite 280, Suite 500SANTA MONICA, CA, United States 90401
Phone
310-598-5410
Fax
302-636-5454

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$121.0M
Revenue (TTM)
$43.9M
Shares Outstanding
4.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.64
EPS
$0.05
Book Value
$8.34
P/E Ratio
528.7x
Price/Sales (TTM)
2.8
Price/Cash Flow (TTM)
72.0x
Operating Margin
6.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.